Treatment of Central Serous Chorioretinopathy Complicated by Secondary Choroidal Neovascularisation

Secondary choroidal neovascularisation (CNV) is the most common complication of chronic central serous chorioretinopathy (CSC). When CSC progresses to this stage, it introduces an additional neovascular process that drives further visual deterioration and requires a targeted treatment approach.

Clinical scenario

Central serous chorioretinopathy complicated by secondary choroidal neovascularisation — which may present with subretinal haemorrhage, lipid, subretinal fluid, or intraretinal fluid. This complication calls for an active intervention strategy distinct from uncomplicated CSC.

Treatment goals

Improvement in visual acuity
Decrease in central macular thickness
Decrease in foveal serous retinal detachment

Treatment approach

Partial overview: The current evidence-based approach involves intravitreal therapy directed at the neovascular process. The complete protocol — including agent selection, dosing schedule, and monitoring criteria — is detailed in the full regimen.

Instant Access to Structured Evidence-Based Regimens

References

The most common complication of chronic CSC is development of secondary CNV, which may present with subretinal haemorrhage, lipid, SRF or intraretinal fluid (IRF).

In cases of CSC complicated by secondary CNV, patients benefit from intravitreal anti-VEGF therapy with an improvement in visual acuity, decrease in CMT, and decrease in foveal serous retinal detachment.

DOI: 10.1111/ceo.14201

View source ↗